<div><p><b>Background: </b>Human pluripotent stem cell (PSC) derived hepatocyte-like cells and primary human hepatocytes applications for clinical or research uses is dependent on the ability to generate phenotypically and functionally relevant hepatocytes or hepatocyte-containing constructs.
<div><p><b>Background:</p> </b><p>The mechanisms contributing to the progression to NASH in patients with NAFLD are unclear. Our central hypothesis is that the inability of hepatic mitochondria to enhance nutrient oxidation in the setting of nutrient oversupply plays a key role in the progression of liver disease in NAFLD. The aim of this study was to explore the relationship between adipose tissue insulin resistance (IR), liver fat, and <em>in vivo</em> hepatic mitochondrial function.</p>
<div><p><b>Background:</p> </b><div><p><span lang="EN-US">Current guidelines for the diagnosis of HRS-AKI require the use of albumin as volume expander to exclude pre-renal azotemia. The treatment of HRS-AKI (hepatorenal syndrome) also recommends the use of terlipressin with albumin at a dose of 20-40g per day. However, the optimal dose of albumin to be given in the pre- and during treatment remains unclear.
<div><p><b>Background:</p> </b><p>In patients with Budd Chiari syndrome (BCS), the current treatment guidelines recommend a step-up approach starting with lifelong anticoagulation with low-molecular-weight heparin (LMWH) or vitamin K antagonists (VKA). Although direct oral anticoagulants (DOAC) may simplify patient management, there is limited data on the safety and efficacy of DOAC in patients with BCS. This study used a large research network to compare the outcomes of patients with BCS treated with DOACs, LMWH, and VKAs.</p>
<div><p><strong><b>Background:</strong> </b><span class="NormalTextRun SCXW107492957 BCX8">Hepatitis C Virus (HCV) is a blood-borne viral pathogen resulting in hepatic inflammation that – if left untreated – may lead to advanced liver disease, hepatocellular carcinoma, and death. With the advent of improved treatment modalities, several national, state, and local governing bodies have called for HCV eradication.
<div><p><b>Background: </b>Risk stratification in non-alcoholic fatty liver disease (NAFLD) using non-invasive scores including Fibrosis-4 (FIB4) and NAFLD fibrosis score (NFS) is recommended by clinical guidelines. However, FIB4 and NFS values are indeterminate in 20-50% of patients with NAFLD. We aimed to develop machine learning models to improve upon FIB4 and NFS, especially in the indeterminate-risk range.</p>
<div><p><b>Background: </b>Environmental pollutants are associated with disrupted hepatic metabolism and NAFLD. A pilot study (n=140) presented at AASLD elucidated exposures and metabolic pathways associated with NAFLD severity. To confirm these findings, a larger cross-sectional multi-‘omics study was performed in subjects with NAFLD. </p>
<div><p><b>Background: </b>Treatment of CHB with JNJ-3989 and NA ± JNJ-6379 has shown profound reductions in serum hepatitis B viral (HBV) markers. The INSIGHT study aims to assess intrahepatic changes in virological and immunological markers with JNJ-3989 based treatment in CHB patients.</p>
<div><p><b>Background: </b>With the ongoing opioid epidemic, hepatitis C virus (HCV) prevalence in women of childbearing potential has increased in North America. As pregnancy may be the only time many women interact with the healthcare system, it presents an opportune time for HCV screening and linkage to care. Poor postpartum follow-up may justify treatment in pregnancy, but there is currently little known about the cascade of care for women of childbearing potential with HCV in pregnancy or postpartum.</p>
<div><p><b>Background: </b>Providers at community hospitals often seek to transfer hospitalized patients with advanced liver disease to tertiary/quaternary care hospitals for further management due to lack of expertise in caring for these patients. However, it is possible to co-manage such patients at local hospitals by providing virtual consultation by tertiary care hepatologists via inpatient telehepatology (INP-TH) consultation.